Navigation Links
Gene Network Sciences Announces Michael Gilman as Board Member

CAMBRIDGE, Mass., Feb. 24 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has named Michael Gilman, Ph.D., Founder and Chief Executive Officer of Stromedix, Inc. and former Executive Vice President of Research at Biogen Idec, to its Board of Directors.

Dr. Gilman has been Founder and Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ARIAD Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology. He also serves on the Board of Directors of EPIX Pharmaceuticals, Inc.

"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our REFS(TM) platform to accelerate pharma drug research and development," said Colin Hill, CEO of GNS. "I am looking forward to leveraging his experiences to create maximum impact for our partners."

"I was drawn to GNS by the power of the supercomputer-driven REFS(TM) platform to enable both new forms of discovery and new approaches to personalized medicine. The industry is at a crossroads, with advances in DNA sequencing finally paving the way to a more systematic exploration of disease biology and drug response markers. Data is no longer the bottleneck -- the analysis is. That's why I see technology such as GNS's as the missing link," said Dr. Gilman.

About Gene Network Sciences

Gene Network Sciences ( is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
2. Yongye Biotechnology International to Expand its Network of Branded Stores
3. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
4. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
5. HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training
6. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
7. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
8. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
9. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
10. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
11. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
Post Your Comments:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):